Neuronetics Stock-Based Compensation 2017-2024 | STIM
Neuronetics stock-based compensation from 2017 to 2024. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
| Neuronetics Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2024 | $6 |
| 2023 | $7 |
| 2022 | $9 |
| 2021 | $8 |
| 2020 | $4 |
| 2019 | $3 |
| 2018 | $2 |
| 2017 | $0 |
| 2016 | $0 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.301B | $0.075B |
| Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. | |||